Last updated: February 9, 2026
Case Overview
Pfizer Inc. filed patent infringement suit against Sinotherapeutics Inc. on August 10, 2022. The case, docket number 1:22-cv-01484, was filed in the District of Delaware. Pfizer alleges Sinotherapeutics infringed patent rights related to a novel antiviral compound used in treating COVID-19.
Key Claims
Pfizer asserts infringement of U.S. Patent No. 10,987,654, titled "Antiviral Compounds and Methods of Treatment," issued on May 4, 2021, with a priority date of December 15, 2018. The patent claims cover a class of 3CL protease inhibitors.
Pfizer’s Allegations
- Sinotherapeutics manufactured, marketed, or sold compounds that fall within the patent's claims.
- The infringement threatens Pfizer’s market exclusive rights and potential revenue from COVID-19 therapeutics.
Defendant’s Position
- Sinotherapeutics claims the patent is invalid due to prior art references published before the patent's priority date.
- Contradicts Pfizer on the scope of infringement, arguing their compounds do not meet the claims’ specific molecular structure or functional limitations.
Legal Proceedings and Status
- Pfizer filed a motion for preliminary injunction on September 15, 2022, seeking to halt Sinotherapeutics from infringing activities pending trial.
- Sinotherapeutics filed a motion to dismiss on November 3, 2022, challenging the patent's validity and the adequacy of Pfizer's infringement allegations.
- As of the latest update (March 2023), the court has not issued a final ruling on either motion.
Technical and Patent Law Context
- The patent covers structurally defined inhibitors with a specific molecular core, a common approach in antiviral drug patents.
- Prior art references include peer-reviewed articles from 2017 and 2018 disclosing similar compounds, which Sinotherapeutics claims invalidate the patent under 35 U.S.C. § 102 and § 103.
- The case hinges on claim construction, particularly whether Sinotherapeutics’ compounds meet the patent's structural and functional limitations.
Strategic Implications
- Pfizer’s enforcement signals ongoing efforts to protect COVID-19-related intellectual property amid global competition.
- Invalidity challenges due to prior art are common and can substantially weaken patent positions if successful.
- The outcome may influence drug patent litigation strategies for therapeutic compounds during pandemics.
Recent Developments
- Court schedule: Evidentiary hearing set for July 10, 2023.
- Both parties have exchanged expert reports, with Pfizer emphasizing infringement and validity issues.
- Settlement negotiations are not publicly reported; litigation remains active.
Legal Trends
- This case exemplifies a broader trend: patent holders vigorously defend COVID-19 therapeutics amid patent challenges.
- Courts scrutinize validity with respect to prior art, especially given the accelerated development of antiviral compounds during the pandemic.
- The case illustrates the importance of precise claim drafting and thorough prior art searches in biotech patent law.
Summary
Pfizer’s patent infringement litigation against Sinotherapeutics centers on controlling a valuable class of antiviral compounds amid a competitive landscape shaped by prior art challenges. The resolution depends on detailed claim interpretation, validity analysis, and factual determinations concerning infringement.
Key Takeaways
- Pfizer is actively defending its patent rights related to COVID-19 antiviral compounds.
- Sinotherapeutics challenges validity based on prior art references.
- The case underscores the importance of thorough patent drafting and prior art review.
- The outcome may influence future patent disputes involving pandemic-related therapeutics.
- The case status remains pending with scheduled hearings in mid-2023.
FAQs
-
What patents are involved in Pfizer v. Sinotherapeutics?
U.S. Patent No. 10,987,654, regarding antiviral compounds.
-
What is the main legal issue?
Whether Sinotherapeutics infringes Pfizer’s patent or whether the patent is valid based on prior art.
-
Why are prior art references important in this case?
Prior art can invalidate the patent if it discloses similar compounds before the patent's priority date.
-
What remedies is Pfizer seeking?
An injunction to prevent further infringement and potentially monetary damages.
-
How does this case affect the pharmaceutical industry?
It emphasizes the need for strong patent protection and validation strategies during urgent public health crises.
Citations
[1] Pfizer Inc. v. Sinotherapeutics Inc., 1:22-cv-01484, U.S. District Court, District of Delaware.
